A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision (PROSPECT)

Brief description of study

If you have been diagnosed with locally advanced rectal cancer, you may qualify for a clinical trial comparing standard treatment of chemotherapy and radiation or chemotherapy using a combination regimen FOLFOX in combination with selective use of standard treatment. The standard treatment for locally advanced rectal cancer involves chemotherapy and radiation, known as 5FUCMT, (the chemotherapy drugs 5-fluorouracil/capecitabine and radiation therapy) prior to surgery. Purpose The goal of the study is to compare the effects, both good and bad, of the standard treatment of chemotherapy and radiation (5FUCMT) to chemotherapy using a combination regimen known as FOLFOX, (drugs 5-fluorouracil (5-FU), oxaliplatin and leucovorin) and selective use of the standard treatment, depending on how well the cancer shrinks in response to the FOLFOX.


Clinical Study Identifier: S12-03104
ClinicalTrials.gov Identifier: NCTS12-03104


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.